|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
CONCURRENT USE MAY BE UNDERTAKEN CAREFULLY AS BOTH DRUGS ARE NEUROTOXIC
|
CONCURRENT USE MAY BE UNDERTAKEN CAREFULLY AS BOTH DRUGS ARE NEUROTOXIC
|
CONCURRENT USE MAY BE UNDERTAKEN CAREFULLY AS BOTH DRUGS ARE NEUROTOXIC
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
CONCOMITANT USE WITH PLATELT INHIBITORS, SUCH AS SALICYLATES, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELT INHIBITORS, SUCH AS SALICYLATES, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELT INHIBITORS, SUCH AS SALICYLATES, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELT INHIBITORS, SUCH AS SALICYLATES, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELT INHIBITORS, SUCH AS SALICYLATES, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELT INHIBITORS, SUCH AS SALICYLATES, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELT INHIBITORS, SUCH AS SALICYLATES, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELT INHIBITORS, SUCH AS SALICYLATES, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELT INHIBITORS, SUCH AS SALICYLATES, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELT INHIBITORS, SUCH AS SALICYLATES, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELT INHIBITORS, SUCH AS SALICYLATES, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION WITH THE DRUG OR USING IT WITHIN 14 DAYS OF DISCONTINUING TREATMENT WITH THESE DRUGS MAY LEAD TO SERIOUS SIDE EFFECTS
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING DUE TO EFFECT ON PLATELET FUNCTION
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING DUE TO EFFECT ON PLATELET FUNCTION
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING DUE TO EFFECT ON PLATELET FUNCTION
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING DUE TO EFFECT ON PLATELET FUNCTION
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING DUE TO EFFECT ON PLATELET FUNCTION
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING DUE TO EFFECT ON PLATELET FUNCTION
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING DUE TO EFFECT ON PLATELET FUNCTION
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING DUE TO EFFECT ON PLATELET FUNCTION
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING DUE TO EFFECT ON PLATELET FUNCTION
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING DUE TO EFFECT ON PLATELET FUNCTION
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING DUE TO EFFECT ON PLATELET FUNCTION
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING DUE TO EFFECT ON PLATELET FUNCTION
|